Five minutes at a time: what our founder told the FDA
Our founder spoke five times at the FDA's Pharmacy Compounding Advisory Committee over two days in July 2026. Every word is published here, with the webcast timecode for each statement.
Where it standsThe statements are public record. As of September 18, 2026, the FDA hadn't posted an official transcript.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met at White Oak in Silver Spring, Maryland, to consider a group of peptides proposed for compounding. The meeting included an open public hearing, which is the part where anyone who registers gets a few minutes at a podium. Mike Stone, who founded ReVia, took five of those slots.
He went there to tell the committee that his market is gray, that he's in it, and that he wants it regulated. Suppliers don't usually say that at a hearing about restricting what they sell.
What he spoke on
| Day | Substance | Slot | Webcast |
|---|---|---|---|
| Day 1 | BPC-157 | Speaker 2, 5 min | 52:39–56:48 |
| Day 1 | KPV | Speaker 1, 3 min | 5:17:10–5:20:35 |
| Day 1 | TB-500 | Speaker 2, 3 min | 8:21:42–8:24:12 |
| Day 2 | Emideltide (DSIP) | Speaker 2, 4 min | 1:17:10–1:19:26 |
| Day 2 | Semax | Speaker 1, 4 min | 6:12:03–6:15:05 |
Why we publish them whole
A statement to a federal advisory committee is a primary source. Quote one sentence of it on a product page and you've turned it into marketing. Publish all of it with the timecode, and a reader can go check that the sentence wasn't doing work the rest of the paragraph would have undone.
The FDA hadn't posted an official transcript when this was written. We transcribed what's published here from the FDA's own webcast recordings and cleaned up caption errors and stutters, with nothing added and nothing reordered. When the FDA's version comes out, we'll check ours against it and correct any differences.
What a recommendation is
The committee advises. It doesn't decide. Nothing said at that meeting, and nothing voted on at it, changed what a pharmacy could lawfully compound the day it ended. Any page that implies otherwise, ours included, is wrong.
Where ReVia stands
A supplier who wants this category regulated should say so where it counts: on the record, under his own name. Then he should publish what he said without trimming it.
Sources
Every factual claim above is numbered to one of these. Where a primary document exists, it is linked in preference to anyone’s summary of it.
- [1]
U.S. Food and Drug Administration
The meeting notice, agenda and materials.
- [2]
U.S. Food and Drug Administration · July 23, 2026
The recording the Day 1 timecodes refer to.
- [3]
U.S. Food and Drug Administration · July 24, 2026
The recording the Day 2 timecodes refer to.
- [4]Docket FDA-2025-N-6895Regulations.gov
Regulations.gov
Holds the written comment filed to the docket, FDA-2025-N-6895-0071, received June 10, 2026.
Related
This is reporting and commentary, and it isn’t legal advice. Regulatory status is described as we understand it on the date shown. Compounds mentioned are for research use only and are not for human or animal consumption.